MannKind (MNKD) News Today $5.22 -0.01 (-0.19%) Closing price 04:00 PM EasternExtended Trading$5.21 -0.01 (-0.11%) As of 04:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period MannKind (MNKD) Gets a Buy from Cantor FitzgeraldMarch 22 at 8:25 PM | markets.businessinsider.comMannKind (NASDAQ:MNKD) Rating Increased to Buy at StockNews.comStockNews.com upgraded MannKind from a "hold" rating to a "buy" rating in a research note on Wednesday.March 20, 2025 | marketbeat.comVictory Capital Management Inc. Purchases 171,537 Shares of MannKind Co. (NASDAQ:MNKD)Victory Capital Management Inc. increased its position in MannKind Co. (NASDAQ:MNKD - Free Report) by 358.6% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 219,367 shares of the biopharmaceutical company'sMarch 19, 2025 | marketbeat.comBrokerages Set MannKind Co. (NASDAQ:MNKD) Target Price at $9.21March 19, 2025 | americanbankingnews.comBank of New York Mellon Corp Grows Holdings in MannKind Co. (NASDAQ:MNKD)Bank of New York Mellon Corp raised its position in shares of MannKind Co. (NASDAQ:MNKD - Free Report) by 7.0% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 789,760 shares of the biopharmaceuticalMarch 18, 2025 | marketbeat.comMannKind Co. (NASDAQ:MNKD) Receives Consensus Rating of "Buy" from AnalystsMannKind Co. (NASDAQ:MNKD - Get Free Report) has received a consensus recommendation of "Buy" from the eight brokerages that are currently covering the stock, MarketBeat.com reports. Seven analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation toMarch 16, 2025 | marketbeat.comMannKind Target of Unusually High Options Trading (NASDAQ:MNKD)MannKind Co. (NASDAQ:MNKD - Get Free Report) was the target of some unusual options trading activity on Thursday. Investors acquired 3,211 call options on the stock. This is an increase of approximately 63% compared to the typical volume of 1,971 call options.March 14, 2025 | marketbeat.comMannKind Corporation Showcases Positive Outcomes of Inhaled Insulin at ATTD 2025 with Anticipated sNDA Filing for Pediatric Use in 2025March 10, 2025 | quiverquant.comMannKind Showcases Efficacy, Safety, and Mealtime Control Data from Recent Pediatric and Adult Studies of Afrezza® at the ATTD Conference, March 19-22March 10, 2025 | globenewswire.comMannKind (NASDAQ:MNKD) Upgraded by StockNews.com to Buy RatingStockNews.com upgraded MannKind from a "hold" rating to a "buy" rating in a report on Friday.March 7, 2025 | marketbeat.comCarrera Capital Advisors Takes $1.02 Million Position in MannKind Co. (NASDAQ:MNKD)Carrera Capital Advisors purchased a new position in MannKind Co. (NASDAQ:MNKD - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 159,165 shares of the biopharmaceutical company's stock,March 5, 2025 | marketbeat.comMannKind Corporation Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting NowMarch 1, 2025 | uk.finance.yahoo.comCantor Fitzgerald Raises Earnings Estimates for MannKindMannKind Co. (NASDAQ:MNKD - Free Report) - Equities researchers at Cantor Fitzgerald boosted their FY2024 earnings per share estimates for MannKind in a research note issued to investors on Wednesday, February 26th. Cantor Fitzgerald analyst O. Brayer now anticipates that the biopharmaceutical coMarch 1, 2025 | marketbeat.comWedbush Reaffirms "Outperform" Rating for MannKind (NASDAQ:MNKD)Wedbush restated an "outperform" rating and set a $11.00 target price on shares of MannKind in a research note on Thursday.February 28, 2025 | marketbeat.comMannKind (NASDAQ:MNKD) Raised to Buy at StockNews.comStockNews.com raised shares of MannKind from a "hold" rating to a "buy" rating in a research note on Wednesday.February 28, 2025 | marketbeat.comMannKind (NASDAQ:MNKD) Announces Quarterly Earnings ResultsMannKind (NASDAQ:MNKD - Get Free Report) announced its earnings results on Wednesday. The biopharmaceutical company reported $0.03 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.03. MannKind had a negative return on equity of 17.74% and a net margin of 8.07%.February 27, 2025 | marketbeat.comMannKind Corporation (NASDAQ:MNKD) Q4 2024 Earnings Call TranscriptFebruary 27, 2025 | msn.comAnalysts Are Bullish on These Healthcare Stocks: Sarepta Therapeutics (SRPT), MannKind (MNKD)February 27, 2025 | markets.businessinsider.comMannKind (NASDAQ:MNKD) Stock Price Down 6.1% - Should You Sell?MannKind (NASDAQ:MNKD) Stock Price Down 6.1% - Time to Sell?February 27, 2025 | marketbeat.comMannKind Q4 Review: Solid Financials, But Tyvaso DPI's Market Share In QuestionFebruary 27, 2025 | seekingalpha.comWells Fargo Sticks to Its Buy Rating for MannKind (MNKD)February 27, 2025 | markets.businessinsider.comMannKind Corp (MNKD) Q4 2024 Earnings Call Highlights: Record Revenue Growth and Strategic ...February 27, 2025 | gurufocus.comMannKind files automatic mixed securities shelfFebruary 27, 2025 | markets.businessinsider.comMannKind Stock Surges After-Hours On Q4 Revenue Beat, Debt Reduction As Retail Investors Celebrate ‘Amazing Comeback’February 27, 2025 | msn.comMannKind (MNKD) Q4 2024 Earnings Call TranscriptFebruary 27, 2025 | finance.yahoo.comQ4 2024 MannKind Corp Earnings Call TranscriptFebruary 27, 2025 | gurufocus.comMannKind Corporation (MNKD) Q4 2024 Earnings Call TranscriptFebruary 26, 2025 | seekingalpha.comMannKind: Q4 Earnings SnapshotFebruary 26, 2025 | chron.comMannKind reports Q4 EPS 3c, consensus 3cFebruary 26, 2025 | markets.businessinsider.comMannkind stock gains amid Q4 report, business updateFebruary 26, 2025 | msn.comMannKind Corp Q4 Earnings: EPS Meets Estimates at $0. ...February 26, 2025 | gurufocus.comMannKind Corp (MNKD) Reports Strong 2024 Financial Results and Strategic DevelopmentsFebruary 26, 2025 | gurufocus.comMannKind Corporation Reports 2024 Revenues of $286M, Achieving 43% Growth Over Previous YearFebruary 26, 2025 | quiverquant.comMannKind Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business UpdateFebruary 26, 2025 | globenewswire.comMannKind Corp (MNKD) Q4 2024 Earnings Report Preview: What To ExpectFebruary 25, 2025 | gurufocus.comMannKind (MNKD) Expected to Announce Earnings on WednesdayMannKind (NASDAQ:MNKD) will be releasing earnings after the market closes on Wednesday, February 26, Financial Modeling Prep reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=336672)February 24, 2025 | marketbeat.comMannKind Corp (MNKD) Announces Upcoming Release of 2024 Financial ResultsFebruary 20, 2025 | gurufocus.comMannKind Corporation to Hold 2024 Fourth Quarter and Full Year Financial Results Conference Call on February 26, 2025February 19, 2025 | globenewswire.comMannKind (MNKD) Expected to Announce Earnings on TuesdayMannKind (NASDAQ:MNKD) will be releasing earnings before the market opens on Tuesday, February 25, Financial Modeling Prep reports.February 18, 2025 | marketbeat.comMannKind initiated with an Outperform at WedbushFebruary 10, 2025 | markets.businessinsider.comWedbush Initiates Coverage on MannKind (NASDAQ:MNKD)Wedbush began coverage on shares of MannKind in a report on Monday. They issued an "outperform" rating and a $11.00 price target on the stock.February 10, 2025 | marketbeat.comSG Americas Securities LLC Has $182,000 Stock Position in MannKind Co. (NASDAQ:MNKD)SG Americas Securities LLC lessened its position in MannKind Co. (NASDAQ:MNKD - Free Report) by 67.4% in the fourth quarter, according to its most recent disclosure with the SEC. The firm owned 28,314 shares of the biopharmaceutical company's stock after selling 58,461 shares during the period. SGFebruary 9, 2025 | marketbeat.comMannKind to Present at Upcoming Investor ConferencesFebruary 6, 2025 | uk.finance.yahoo.comMannKind Corp (MNKD) Announces Participation in Key Investor ConferencesFebruary 6, 2025 | gurufocus.comCalamos Advisors LLC Has $1.19 Million Stock Holdings in MannKind Co. (NASDAQ:MNKD)Calamos Advisors LLC cut its stake in shares of MannKind Co. (NASDAQ:MNKD - Free Report) by 41.5% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 184,661 shares of the biopharmaceutical company's stock after selling 131,021 shares during the period. CalFebruary 6, 2025 | marketbeat.comTop Picks 2025- MannKind MNKDFebruary 4, 2025 | finance.yahoo.comMannKind Corporation's (NASDAQ:MNKD) institutional investors lost 4.0% over the past week but have profited from longer-term gainsFebruary 2, 2025 | finance.yahoo.comMannKind Co. (NASDAQ:MNKD) Given Consensus Rating of "Buy" by BrokeragesMannKind Co. (NASDAQ:MNKD - Get Free Report) has received a consensus rating of "Buy" from the eight ratings firms that are presently covering the firm, Marketbeat.com reports. Seven analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The averageJanuary 25, 2025 | marketbeat.comCantor Fitzgerald Forecasts MannKind FY2025 EarningsMannKind Co. (NASDAQ:MNKD - Free Report) - Stock analysts at Cantor Fitzgerald issued their FY2025 earnings estimates for MannKind in a research report issued on Tuesday, January 21st. Cantor Fitzgerald analyst O. Brayer forecasts that the biopharmaceutical company will post earnings per share ofJanuary 24, 2025 | marketbeat.comBrokers Issue Forecasts for MannKind FY2025 EarningsMannKind Co. (NASDAQ:MNKD - Free Report) - Investment analysts at Cantor Fitzgerald issued their FY2025 EPS estimates for shares of MannKind in a report issued on Tuesday, January 21st. Cantor Fitzgerald analyst O. Brayer anticipates that the biopharmaceutical company will post earnings of $0.34January 23, 2025 | marketbeat.com Remove Ads Get MannKind News Delivered to You Automatically Sign up to receive the latest news and ratings for MNKD and its competitors with MarketBeat's FREE daily newsletter. Email Address MNKD Media Mentions By Week MNKD Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. MNKD News Sentiment▼0.970.68▲Average Medical News Sentiment MNKD News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. MNKD Articles This Week▼44▲MNKD Articles Average Week Remove Ads Get MannKind News Delivered to You Automatically Sign up to receive the latest news and ratings for MNKD and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Alkermes News Ionis Pharmaceuticals News Amicus Therapeutics News Ligand Pharmaceuticals News Dynavax Technologies News BioCryst Pharmaceuticals News Celldex Therapeutics News Novavax News OPKO Health News Geron News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:MNKD) was last updated on 3/25/2025 by MarketBeat.com Staff From Our PartnersYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MannKind Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share MannKind With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy MNKD Stock Free MNKD Stock Alerts